abstract |
The present invention relates to the treatment of diseases characterized by overexpression of ErbB2. More specifically, the present invention relates to a method for treating a human patient diagnosed with a cancer overexpressing ErbB2 or a patient suspected of such cancer in combination with an anti-ErbB2 antibody and a chemotherapeutic agent other than anthracycline such as doxorubicin or epirubicin. will be. |